ALNY
ALNYLAM PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$260.10
−2.26%Price chart
Aug 7Aug 12Aug 17Aug 20Aug 25Aug 28Sep 2Sep 8
ValuationView details →
P/E (Fwd)
30.7x
EV/EBITDA
28.5x
Market Cap
$34.80B
MomentumView details →
1D Return
−2.26%
YTD Return
−34.51%
RSI (14)
58.1
ValuationView details →
P/E (Fwd)
30.7x
EV/EBITDA
28.5x
Market Cap
$34.80B
RSI (14)
58.1
MomentumView details →
1D Return
−2.26%
YTD Return
−34.51%
SummaryUpdated Jun 1, 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a pioneering biopharmaceutical company founded in 2002 and headquartered in Cambridge, Massachusetts. The company went public in 2004 and has established itself as a leader in RNA interference (RNAi) therapeutics, a revolutionary approach to treating diseases by silencing specific genes that cause illness. Alnylam has successfully commercialized multiple RNAi-based medicines and maintains a robust pipeline targeting both rare genetic diseases and more prevalent conditions including cardiovascular, metabolic, and neurological disorders.
Similar companies
Latest newsMore news →
AstraZeneca announced on Friday that its Phase 3 clinical trial for an experimental silencer drug in ATTR-CM patients failed to show additional benefit over existing stabilizer therapy, impacting its partnership with Ionis Pharmaceuticals and the broader market.12d agoAlnylam Pharmaceuticals announced it will present new clinical and real-world data across its ATTR and hypertension programs at the ESC Congress 2026 in Munich, Germany, from August 28-31, 2026.16d ago